NAD+ Supplementation as a Novel Approach to cURIng HCC?

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni

UvrD Helicase Unwinds DNA One Base Pair at a Time by a Two-Part Power Stroke Jae Young Lee, Wei Yang Cell Volume 127, Issue 7, Pages (December.

Cost of Unneeded Proteins in E. coli Is Reduced after Several Generations in Exponential Growth Irit Shachrai, Alon Zaslaver, Uri Alon, Erez Dekel Molecular.

Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.

CDK Inhibitors: Cell Cycle Regulators and Beyond Arnaud Besson, Steven F. Dowdy, James M. Roberts Developmental Cell Volume 14, Issue 2, Pages

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

Gastrulation Movements: the Logic and the Nuts and Bolts Maria Leptin Developmental Cell Volume 8, Issue 3, Pages (March 2005) DOI: /j.devcel

Septic Shock: On the Importance of Being Tolerant

T-ALL: Home Is where the CXCL12 Is

Liver Cancer Checks in When Bile Acid Clocks Out

NCOA5, IL-6, Type 2 Diabetes, and HCC: The Deadly Quartet

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Kenneth L. Scott, Scott Powers Cancer Cell

Nomeda Girnius, Roger J. Davis Cancer Cell

Lymphotoxins: New Targets for Hepatocellular Carcinoma

Accelerating drug discovery: Open source cancer cell biology?

An Alternative Sugar Fuels AML

A Time to Divide: Does the Circadian Clock Control Cell Cycle?

Achim Weber, Mathias Heikenwalder Cancer Cell

Ana Magalhães, Henrique O. Duarte, Celso A. Reis Cancer Cell

Data Triumph at C Cancer Cell

The DNA Damage Response: Ten Years After

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

No Need for Constant Help: Human IgG2 Antibodies Have an Autonomous Agonistic Activity for Immunotherapy of Cancer Anja Lux, Falk Nimmerjahn Cancer.

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

The Wind God Promotes Lung Cancer

Doria Filipponi, Julius Muller, Alexander Emelyanov, Dmitry V. Bulavin

Fibrinogen in the Nervous System: Glia Beware

A Zygotic Checkpoint for Unrepaired Lesions

How To Choose a Good Scientific Problem

AMPK Keeps Tumor Cells from Starving to Death

Autophagy, Apoptosis, and the Influenza Virus M2 Protein

NCOA5, IL-6, Type 2 Diabetes, and HCC: The Deadly Quartet

MicroRNAs and Parallel Stem Cell Lives

ER Stress in Dendritic Cells Promotes Cancer

Volume 22, Issue 6, Pages (December 2012)

Eukaryotic Transcription Activation: Right on Target

Characterizing the Killer Colorectal Carcinomas

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Volume 28, Issue 5, Pages (November 2015)

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit Kristen E. Pauken,

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Easy Stress Relief by EZH2

Kenneth L. Scott, Scott Powers Cancer Cell

Volume 143, Issue 6, (December 2010)

Inflammation, ROS, and Mutagenesis

Linking DNA Damage, NAD+/SIRT1, and Aging

Mst Out and HCC In Cancer Cell

RIPK3 Slams the Brake on Leukemogenesis

Splicing and Dicing MYC-Mediated Synthetic Lethality

Khalid S. Mohammad, Theresa A. Guise Cancer Cell

TFIID and MYB Share a Therapeutic Handshake in AML

The DNA Damage Response: Ten Years After

How To Choose a Good Scientific Problem

Chapter 78 Vaccination and Screening in Cervical Cancer

Macrophage Metabolism Shapes Angiogenesis in Tumors

c-Raf in KRas Mutant Cancers: A Moving Target

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX Jean-Christophe Marine Cancer Cell Volume.

Volume 12, Issue 6, Pages (December 2007)

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome

Presentation transcript:

NAD+ Supplementation as a Novel Approach to cURIng HCC? Ingmar Mederacke, Robert F. Schwabe Cancer Cell Volume 26, Issue 6, Pages 777-778 (December 2014) DOI: 10.1016/j.ccell.2014.11.011 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 The URI/NAD+ Pathway Can Be Targeted for the Prevention or Treatment of HCC Increased expression of URI in inflamed or injured liver leads to AhR- and/or ER-mediated reduction of NAD+, leading to DNA damage, which, in turn, triggers dysplasia, adenoma, and HCC development. Blocking URI, increasing AhR or ER activity, or restoring NAD+ levels can be employed for the prevention or treatment of HCC. Cancer Cell 2014 26, 777-778DOI: (10.1016/j.ccell.2014.11.011) Copyright © 2014 Elsevier Inc. Terms and Conditions